

WHAT IS CLAIMED IS:

1. An isolated antibody that specifically binds to human P210 BCR-ABL fusion protein junction (SEQ ID NO: 1), but does not bind wild type BCR or c-ABL.
- 5 2. The antibody of claim 1, wherein said antibody binds a polypeptide comprising residues 94 to 108 of SEQ ID NO: 1.
3. The antibody of claim 1, wherein said antibody binds a polypeptide comprising residues 97 to 101 of SEQ ID NO: 1.
4. The antibody of claim 1, wherein said antibody is polyclonal.
- 10 5. The antibody of claim 1, wherein said antibody is monoclonal.
6. An immortalized cell line producing the antibody of claim 5.
7. The cell line of claim 6, wherein said cell line is a hybridoma.
8. The cell line of claim 7, wherein said hybridoma is ATCC Accession No. PTA-5851.
- 15 9. A method for detecting the presence of P210 BCR-ABL fusion protein in a biological sample, said method comprising the steps of:
 - (a) contacting a biological sample potentially, or suspected of, containing P210 BCR-ABL fusion protein with at least one antibody of claim 1, under conditions suitable for formation of
 - 20 an antibody-BCR-ABL fusion protein complex; and

(b) detecting the presence of said complex in said biological sample, wherein the presence of said complex indicates the presence of BCR-ABL fusion protein in said sample.

10. The method of claim 9, wherein said biological sample is obtained
5 from a subject at risk of, or suspected of, having a disease involving BCR-ABL fusion protein expression.

11. The method of claim 10, wherein said disease is chronic myelogenous leukemia (CML).

12. The method of claim 9, wherein said biological sample has been
10 contacted with at least one BCR-ABL inhibitor, or is obtained from a subject treated with such inhibitor.

13. The method of claim 9, wherein said biological sample has been contacted with a compound being tested for inhibition of BCR-ABL activity or expression.

15 14. A method for identifying a compound that modulates expression of P210 BCR-ABL fusion protein in a biological sample, said method comprising the steps of:

(a) contacting a test biological sample with a test compound,
(b) detecting the level of BCR-ABL fusion protein in said test
20 biological sample of step (a) using at least one antibody of claim 1 under conditions suitable for formation of an antibody-BCR-ABL fusion protein complex, and
(c) comparing the level of BCR-ABL fusion protein detected in step (b) with the presence of BCR-ABL fusion protein in a control
25 sample not contacted with said test compound, wherein a

difference in BCR-ABL fusion protein levels in said test and control samples identifies said compound as a compound that modulates expression of BCR-ABL fusion protein.

15. A kit for the detection of P210 BCR-ABL fusion protein in a
5 biological sample, said kit comprising (a) at least one antibody of claim 1
and (b) at least one secondary antibody conjugated to a detectable group.